CryoLogyx
CryoLogyx makes pre-plated assay ready cells. There products enable researchers to carry out months of work in a few days, by removing the need for in house cell culture. Our cell-based products are usable directly from the freezer. This eliminates around 2 weeks of cell expansion and preparatory work, 86% of single use plastic waste, and increases lab productivity and profitability.We started the Innovate UK ICURe programme at the same time as the COVID-19 pandemic and the world began locking down, so I travelled the world via zoom calls in my flat. None the less we were able to talk to multiple experts in the field and speak to CTOs and CEOs across the biotech, medical and even senior VPs and managing directors in the construction sector. We were able to have over 100 insightful conversations and a recommendation to spin out from a panel of experts. This led us to forming CryoLogyx in March 2021 with a combination of grant and seed capital.
Dr Thomas Congdon, CEO, CryoLogyx Ltd
2020
Start Date
University of Warwick
Location
5
Employees
£585k
Grants
£150k
Equity
The Journey
We started the ICURe programme at the same time as the COVID-19 pandemic and the world began locking down, so I travelled the world via zoom calls in my flat. None the less we were able to talk to multiple experts in the field and speak to CTOs and CEOs across the biotech, medical and even senior VPs and managing directors in the construction sector. We were able to have over 100 insightful conversations and a recommendation to spin out from a panel of experts. This led us to forming CryoLogyx in March 2021 with a combination of grant and seed capital.
Dr Thomas Congdon, CEO, CryoLogyx Ltd
Contact Form
What companies had to say about the Innovate UK ICURe programme?
Dr Thomas Congdon
CEO
Future Goals
Our long term mission is to transform biotech R&D by making cell models simple, fast and convenient. If any researcher anywhere in the world can access high quality, easy to use and reproducible experiments on demand, the drug discovery pipeline that feeds biotech innovation will move faster and more freely. The technology we are developing now turns a two week process into a ready to use product, cuts down toxicity testing workflows and dramatically reduces plastic waste and laboratory overheads. Ultimately we will develop a whole range of products that will remove every logistical, workflow and technical barrier to bring new drugs to clinical trial.